NASDAQ:SLGL - Sol Gel Technologies Stock Price, Forecast & News

Sol Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."

Sol Gel Technologies Ltd (NASDAQ:SLGL) released its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.12. The firm earned $4.73 million during the quarter, compared to analyst estimates of $6.56 million. Sol Gel Technologies had a negative return on equity of 71.98% and a negative net margin of 223.99%. View Sol Gel Technologies' Earnings History.

Sol Gel Technologies is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Sol Gel Technologies.

4 brokers have issued 1-year target prices for Sol Gel Technologies' stock. Their forecasts range from $23.00 to $33.00. On average, they expect Sol Gel Technologies' share price to reach $26.50 in the next year. This suggests a possible upside of 117.7% from the stock's current price. View Analyst Price Targets for Sol Gel Technologies.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol Gel Technologies in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sol Gel Technologies.

Headlines about SLGL stock have been trending negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sol Gel Technologies earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Sol Gel Technologies.

Sol Gel Technologies saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 68,600 shares, an increase of 27.5% from the January 15th total of 53,800 shares. Based on an average daily trading volume, of 89,000 shares, the short-interest ratio is presently 0.8 days. Approximately 1.8% of the company's shares are short sold. View Sol Gel Technologies' Current Options Chain.

Some companies that are related to Sol Gel Technologies include Phathom Pharmaceuticals (PHAT), Achillion Pharmaceuticals (ACHN), Radius Health (RDUS), Cytokinetics (CYTK), Endonovo Therapeutics (ENDV), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Applied Therapeutics (APLT), ImmunoGen (IMGN), Homology Medicines (FIXX), Rhythm Pharmaceuticals (RYTM), Dova Pharmaceuticals (DOVA), Collegium Pharmaceutical (COLL), CannTrust (CNTTF) and ANI Pharmaceuticals (ANIP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sol Gel Technologies investors own include Iovance Biotherapeutics (IOVA), Micron Technology (MU), NVIDIA (NVDA), Amarin (AMRN), CareDx (CDNA), eHealth (EHTH), Mylan (MYL), Novavax (NVAX), Tandem Diabetes Care (TNDM) and AbbVie (ABBV).

(SLGL) raised $60 million in an IPO on Thursday, February 1st 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ served as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

Sol Gel Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Phoenix Holdings Ltd. (10.35%), Broadfin Capital LLC (2.56%), Raymond James & Associates (0.17%), Raymond James Financial Services Advisors Inc. (0.16%), Renaissance Technologies LLC (0.07%) and Tower Research Capital LLC TRC (0.02%).

SLGL stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Renaissance Technologies LLC, Raymond James & Associates and Raymond James Financial Services Advisors Inc..

SLGL stock was bought by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd. and Tower Research Capital LLC TRC .

Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SLGL stock can currently be purchased for approximately $12.17.

Sol Gel Technologies has a market capitalization of $248.15 million and generates $130,000.00 in revenue each year. The company earns $-32,200,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. View Additional Information About Sol Gel Technologies.

The official website for Sol Gel Technologies is http://www.sol-gel.com/.

Sol Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403650. The company can be reached via phone at 972-8931-3429 or via email at [email protected]